(Q35091505)

English

Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

3

object named as

Eric Wenzel

0 references

author name string

Seth Hetherington

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Michele Texter

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Eric Wenzel

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Joseph M Patti

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Laurie Reynolds

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Trish Shamp

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Suzanne Swan

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

1 October 2006

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3499-3500

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Pharmacokinetics of therapeutic monoclonal antibodies used in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1610062

8 July 2018

Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1610062

8 July 2018

Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1610062

8 July 2018

Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1610062

8 July 2018

Staphylococcus aureus infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1610062

8 July 2018

Genetic evidence that bound coagulase of Staphylococcus aureus is not clumping factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1610062

8 July 2018

Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1610062

27 September 2018

Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1610062

27 September 2018

Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/17005843

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

1 reference

https://pubmed.ncbi.nlm.nih.gov/17005843

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.00407-06

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

release_7ruf7ujubnbc7bdsiztvnkl5xi

1 reference

https://api.fatcat.wiki/v0/release/7ruf7ujubnbc7bdsiztvnkl5xi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35091505&oldid=2144562689"